Medtronic sues Insulet for allegedly infringing a pair of its patents with Insulet's OmniPod insulin management system for diabetes.
Medtronic 's (NYSE:MDT ) MiniMed subsidiary sued Insulet  (NSDQ:PODD ) for patent infringement, alleging that Insulet's OmniPod insulin management system infringes a pair of MiniMed patents.
The lawsuit, filed Sept. 18 in the U.S. District Court for Central California, alleges that Bedford, Mass.-based Insulet's OmniPod, a wireless insulin delivery system for diabetes, trespasses on a pair of patents that are licensed to Medtronic MiniMed. Both the so-called "'276 patent" and the "'878 patent" are called "External Infusion Device With Remote Programming, Bolus Estimator And/Or Vibration Alarm Capabilities."
Fridley, Minn.-based Medtronic claims that Insulet has known about the alleged infringement of the first patent "since at least April 27, 2005, when Insulet filed a patent application with the United States Patent Office ... which referenced the '276 patent. In addition, in 2007, Medtronic sent Insulet' s then President and CEO, Mr. Duane DeSisto, a letter advising Insulet of the '276 patent," according to court documents.